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Background: The use of a distal filter cerebral protection device with carotid artery stenting is commonplace. There is little
evidence, however, that filters are effective in preventing embolic lesions. This study examined the incidence of embolic
phenomenon during carotid artery stenting with and without filter use.
Methods: This was a prospective, randomized, single-center study of carotid artery stenting with or without a distal
cerebral protection filter. A 1:1 scheme was used to randomize 36 carotid artery stenting procedures in 35 patients.
Diffusion-weighted magnetic resonance imaging (DW MRI) 24 hours after stenting was used to assess the occurrence of
new embolic lesions. Blinded observers calculated lesion number and volume.
Results: The mean age was 78.6  7.0 in the cerebral protection group compared with 74.1  8.7 in the no cerebral
protection group (P  .92). Despite similar average age, the percentage of octogenarians was higher in the cerebral
protection group (61.1% vs 22.2%; P  .04). Two procedures in the cerebral protection group were not successful. One
was completed without protection because of inability to track the filter, and the second was aborted because of severe
tortuosity with a later carotid endarterectomy. New MRI lesions were noted in 72% of the cerebral protection group
compared with 44% in the no cerebral protection group (P  .09). The average number of lesions in these patients was
6.1 and 6.2, respectively, with mean DW MRI lesion size of 16.63 mm3 vs 15.61 mm3 (P  .79 and .49, respectively).
Four strokes occurred (11%), two in each group, in patients aged 75, 80, 82, and 84 years. The only major stroke occurred
in the no cerebral protection group.
Conclusions: The use of filters during carotid artery stenting provided no demonstrable reduction of microemboli, as
expected. Routine use of cerebral protection filters should undergo a more critical assessment before mandatory universal
adoption. ( J Vasc Surg 2008;47:760-5.)The use of carotid artery stenting (CAS) has increased
worldwide since the advent of cerebral protection (CP)
devices. These CP devices include distal balloon occlusion
and proximal balloons with reversal of flow, but by far the
most widely used are those based on distal filter placement
to capture emboli dislodged from the plaque. The filters
typically retain fragments larger than the pore size of
around 100 m but allow passage of smaller particles. The
exact role of CAS in replacing carotid endarterectomy
(CEA) for the treatment of carotid artery stenosis remains
controversial on a number of fronts,1 but there has been
little discussion of the benefit of distal CP devices or their
potential complications.
The use of a filter makes intuitive sense, but there has
been little evidence that it actually reduces the incidence of
stroke during the procedure. Most of the evidence pro-
vided in the literature relies on historical comparisons with
results obtained before the use of CP despite numerous
other unrelated concomitant technical advances.2 Al-
though not powered for such an analysis, the ACCULINK
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760(ARCHeR) trial, which used no CP in the first phase,
over-the-wire filters in the second phase, and the current
rapid-exchange filter in the third phase, failed to show a
difference in 30-day stroke rates between these groups
(4.4%, 5.8%, and 6.2%, respectively).3 The absolute num-
bers were actually better in the first phase with the same
inclusion criteria and enrolling centers, casting some doubt
about the effectiveness of such filters.
The purpose of this study was to examine the risk of
embolization in patients undergoing CAS with and with-
out the use of distal CP filters. Because clinical adverse
events are relatively sparse, the study was designed to use
diffusion-weighted magnetic resonance imaging (DW
MRI) as a more sensitive means of examining the effective-
ness of filter use on avoiding embolic events after CAS.
METHODS
Study design. The study was a prospective, random-
ized, single-center study conducted under an investiga-
tional device exemption from the United States Food and
Drug Administration (FDA). It was approved and moni-
tored by the University of Pittsburgh Institutional Review
Board. All devices used were the RX ACCULINK Carotid
Stent and the RX ACCUNET Embolic Protection System
(Guidant, Menlo Park, Calif). Only one system was used to
diminish any other variables that might complicate data
analysis. The same system used in the national Carotid
Revascularization Endarterectomy vs. Stent Trial (CREST)
was chosen. An independent Data and Safety Monitoring
, mag
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statistician from the Office of Clinical Research, reviewed
all clinical data biannually and authorized the continuation
of the study.
Inclusion and exclusion criteria. Inclusion and ex-
clusion criteria are listed in Table I. All patients were
considered to be in a high-risk category for CEA. As of
January 2006, asymptomatic octogenarians were excluded
from the study amidst mounting evidence of increased
stroke rates in this subgroup of patients with limited poten-
tial clinical benefit.
Procedures. All procedures were performed by one of
three interventionalists credentialed to perform CAS at our
institution, which requires a minimum of 25 CAS proce-
dures for credentialing. Two interventionalists started the
study and the third was credentialed 1 year later. One
(M. S. M.) was present at 33 of the 36 procedures. At 17 of
36 procedures, two of the three interventionalists were
present and working together.
Patients with symptoms 60 days of the procedure
underwent a baseline MRI before CAS. Aspirin and an
additional antiplatelet agent (clopidogrel or ticlopidine if
the patient had an allergy to clopidogrel) were initiated at
least 48 hours and preferably 5 days before CAS. A study
neurologist examined the patients before and 24 hours
after the conclusion of the procedure.
Extracranial and intracranial angiography was per-
formed at the time of the intervention to confirm preoper-
ative imaging before randomization. Once the severity of
the lesion was confirmed and the anatomy judged to be
suitable for CAS, the patient was randomized by 1:1 block
randomization. The patient was notified after the proce-
dure of their randomization status.
The CAS technique involved filter placement in the
appropriate group, predilation with a 4.0-mm balloon,
Table I. Inclusion and exclusion criteria
Inclusion criteria
Age 18 years
Able to understand and give consent
Able to tolerate MRI scan
Angiographic or noninvasive (DUS, CTA, or MRA) evidence of
70% stenosis of CCA or ICA, or both
1 high-risk criteria confirmed by at least 2 physicians (at least 1
vascular surgeon)
1. Cardiac dysfunction (NYHA class III or greater CHF, EF 35
2. Pulmonary dysfunction (documented COPD on
bronchodilators)
3. Multisystem dysfunction
4. General debilitation as documented by primary care physician
5. Age 80 years (only symptomatic octogenarians were allowed
after January 2006)
6. Hostile neck anatomy
CCA,Common carotid artery;CHF, congestive heart failure;COPD, chroni
duplex ultrasound; EF, ejection fraction; ICA, internal carotid artery; MRA
New York Heart Association.stent placement, and postdilation. Heparin was used tomaintain an activated clotting time of250 seconds. Techni-
cal success was considered to be 30% residual stenosis in
the stented segment.
Follow-up. All patients underwent a detailed neuro-
logic exam by the study neurologist, including motor,
sensory, autonomic and cognitive testing, carotid duplex
ultrasound (DUS) imaging, and evaluation for adverse
events before discharge, usually24 hours of the interven-
tion. The same evaluation was repeated at 30 days 1 week
postprocedurally. A DW MRI was performed before dis-
charge, typically on postoperative day 1. The MRI studies
were examined by a blinded neuroradiologist to determine
the presence of acute changes and the number of lesions. A
second blinded investigator then calculated DW MRI le-
sion volume from these studies. Additional follow-up visits
were performed at 6 and 12 months. Restenosis (50%)
was determined by carotid DUS study performed at an
affiliated vascular laboratory using published criteria for
post-CAS stenosis requiring peak systolic velocity 225
cm/s and ratio of2.5.4 Findings consistent with resteno-
sis were confirmed with angiography.
Data analysis. The study was designed to test the
hypothesis that the use of filter protection would decrease
the percentage of patients with embolic events by 75%.
Previous studies had indicated a baseline incidence of em-
boli of 29%, with our estimate that these would be reduced
to 7%.5 Using a two-sided test of independent proportions
and assuming random 1:1 allocation to study groups, we
determined a sample size of 45 patients in each group
would be sufficient to detect the expected difference with
  .05 and power of 0.80. Estimating an approximate
withdrawal rate of 10% from the study, we estimated a need
to enroll 100 patients to meet our expected sample size.
The primary study end point was the percentage of
patients who showed evidence of new ischemic injury after
Exclusion criteria
Intracranial hemorrhage or stroke with mass effect within past
30 days
Residual deficits after ischemic stroke
Allergy to heparin, ticlopidine, or clopidogrel
Any imaging evidence of intraluminal thrombus or highly
calcified lesions thought to be potentially resistant to
angioplasty
uctive pulmonary disease;CTA, computed tomography angiography;DUS,
netic resonance angiography; MRI, magnetic resonance imaging; NYHA,%)
c obstrCAS by DWMRI imaging. Secondary end points included
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discharge and at 30 days. These included the presence of
ipsilateral transient ischemic attack or stroke as determined
by the study neurologist. Other secondary end points in-
cluded restenosis (50%) as determined by ultrasound
imaging at one year.
Serious adverse events were recorded as defined by the
FDA Safety Information and Adverse Event Reporting
Program, and all other adverse events were classified as
“minor” (http://www.fda.gov/medwatch). Major stroke
was defined as any new neurologic deficit that lasted 24
hours with an increase in the score on the National Insti-
tutes of Health stroke scale of 4 points. A minor stroke
was defined as a new neurologic deficit that lasted 24
hours and either resolved completely or did not meet the
criteria for a major stroke. Study end points were analyzed
by the Fisher exact test for dichotomous outcomes and the
Student t test for continuous outcomes. Values of P  .05
were considered significant.
RESULTS
A total of 260 patients were prospectively screened
fromDecember 2003 to January 2006 for CAS, and 35met
inclusion/exclusion criteria and agreed to randomization
to CAS either with or without the use of adjunctive CP.
Baseline characteristics of the patients in this study are
found in Table II. The mean age was 78.6 7.0 in the CP
group compared with 74.1 8.7 in the no CP group (P
.92). Despite similar ages in the two groups, the CP group
had a higher percentage of octogenarians (61.1% vs 22.2%;
P  .04). One patient underwent bilateral CAS at separate
settings (2 months apart), with separate randomization, for
a total of 36 procedures. Ten patients had somewhat unfa-
vorable anatomy (type III arch, significant tortuosity, or
unfavorable lesion characteristics); six of these were in the
no CP group and four in the CP group. The study was
terminated early in agreement with the Data Safety Moni-
toring Board because of unsuccessful recruitment efforts
after device market release and a high likelihood that target
Table II. Baseline characteristics
Variable
Cerebral protectiona
PYes (n  18) No (n  18)
Age, years 78.6  7.0 74.1  8.7 0.92
Octogenarian 11 (61.1) 4 (22.2) 0.04
Hostile neck anatomy 5 (27.8) 7 (38.9) 0.73
Hypertension 14 (77.8) 15 (83.3) 1.0
COPD 1 (5.6) 4 (22.2) 0.34
Hyperlipidemia 9 (50) 10 (55.6) 1.0
Diabetes 5 (27.8) 5 (27.8) 1.0
CAD 9 (50) 13 (72.2) 0.31
Males 13 (72.2) 10 (55.6) 0.49
Symptomatic 4 (22.2) 2 (11.1) 0.66
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease.
aContinuous data are presented as mean  SD; categoric data as num-
ber (%).enrollment was no longer realistic.Patients were analyzed on an intent-to-treat basis. In
one patient in the CP group, the attempt to advance the
filter past a tortuous angulation of the distal internal carotid
artery (ICA) failed, although the stent was deployed suc-
cessfully without protection over the buddy wire that was
used to help pass the filter (Fig). No serious adverse events
occurred as a result of this intervention, although newMRI
lesions were noted. In a second patient in the CP group, the
filter was delivered successfully, but a type III arch and a
tortuous anatomy made stent delivery unsuccessful. New
MRI lesions were also noted in this patient the next day,
without any clinical events. This patient subsequently un-
derwent an uneventful CEA.
Neurologic events. The overall stroke rate was 11%,
with three minor strokes and one major stroke. Other
adverse events are summarized in Table III. All strokes were
ipsilateral on the side of the stented vessel. Themajor stroke
occurred in the group without CP, and an additional minor
stroke occurred in this group (left upper and lower extrem-
ity drift). The other minor strokes occurred in patients with
successful CP deployment. One was associated with severe
vasospasm of the ICA at the area of filter deployment, with
intraoperative mental status changes and arm weakness
after filter placement. This was treated with 200 g of
intra-arterial nitroglycerin, and the spasm resolved 12minutes
later. No angiographic emboli were seen distally at the con-
clusion of the procedure. Multiple small embolic infarcts in
the middle carotid artery territory were seen onMRI the next
day.Three of the strokes, including themajor stroke, occurred
in octogenarians; the fourth was in a 75-year-old patient. In
addition, a 79-year-old hypertensive subject experienced hy-
perperfusion syndromemanifestedbyfluctuating aphasia for 2
days after the procedure, with subsequent complete resolu-
tion. Swelling was noted on MRI. All clinical neurologic
events were seen in asymptomatic patients.
Magnetic resonance imaging findings. New defects
were noted on the postprocedural DW MRI in 13 patients
in the CP group (72%) vs eight patients in the no CP group
(44%; P  .09; Table IV). Ipsilateral lesions (67% vs 39%;
P  .09) were noted in all patients except for one in each
groupwith only contralateral emboli. In those patients with
new lesions, there was no difference between groups in the
average number or mean size of the defects seen on DW
MRI. Lesion frequency was similar between CP and no CP
groups among patients with redo procedures or prior radi-
ation treatment (42%).
All patients with major or minor strokes had evidence of
new MRI defects ipsilateral to the stented side. In general,
MRI lesions were larger in patients who had clinically obvious
events (39.9  42.5 vs 7.2  9.6; P  .22), and the major
stroke patient had the largest cumulative lesion volume at 91.6
mm3. The correlation was not perfect, however; with the next
largest volume, 63.9 mm3, occurring in a patient without a
postoperative neurologic event.
The association between age and the cumulative DW
MRI lesion size was weakly positive (r2 0.467; PNS).
Themean lesion size for those patients aged80 was 3.9
8.3 mm3 vs 17.5  29.6 mm3 (P  .1) in patients 80.
s (arr
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and at least one ipsilateral lesion was identified in 19 (53%)
after the CAS procedure. There was no significant differ-
ence in ipsilateral DWMRI lesions in patients with previous
CEA compared with patients with primary lesions (38% vs
57%, respectively; P  .34).
One-year follow-up. One patient was lost to follow-up
and one patient in each group died of unrelated causes. An
additional patient had an ipsilateral ICA occlusion that devel-
Fig. A, Initial angiogram demonstrated favorable an
B, Advancement of sheath resulted in exaggeration o
unsuccessful. Stenting was accomplished without a filter
subsequently demonstrated bilateral new embolic lesion
Table III. Serious adverse events after carotid artery
stenting
Cerebral protection
Yes (n  18) No (n  18)
Non-Q-wave MI 1 0
Hypotension 2 3
Orthostatic hypotension 1 0
Minor stroke 2 1
Major stroke 0 1
Gastrointestinal bleeding 0 1
Bradycardia (asymptomatic) 0 1
Hyperperfusion syndrome 0 1
ICA vasospasm 1 0
Femoral bleed 0 1
Retroperitoneal hematoma 0 1
ICA, internal carotid artery; MI, myocardial infarction. All P values were
less than .5.
Table IV. Diffusion-weighted magnetic resonance
imaging defects after carotid artery stenting
Defect
Cerebral protection
PYes (n  18) No (n  18)
Any MRI diffusion defect 13 (72%) 8 (44%) .09
Any ipsilateral diffusion
defect
12 (67%) 7 (39%) .09
Average No. of defects 6.1 6.2 NS
DW MRI defect size,
mean mm3
16.63 15.61 NS
DW, Diffusion weighted; MRI, magnetic resonance imaging.oped shortly after the procedure. The patient had a “stringsign” in the ICA distally, and an intracranial ICA occlusion
was not appreciated until after stent placement. The patient
remained asymptomatic. One patient who underwent CAS
withoutCPhad an internal-to-common carotid artery velocity
ratio of 4.9 and underwent angiography confirming only a
30% to 40% stenosis. None of the remaining 30 patients
tested at 1 year had evidence of recurrent stenosis exceed-
ing 50%.
DISCUSSION
The optimal means of performing CAS has been hotly
debated since its inception. Intended to protect the CAS
patient from embolic occurrences, distal embolic filters
have been adopted widely but have failed to gain universal
acceptance. Some interventionalists have gone so far as to
adopt a policy of routine nonuse of protection, demonstrat-
ing favorable results.6 The majority opinion, however, is
reflected in a 2004 editorial declaring that the benefit of CP
is “so intuitively clear that randomized trials cannot be
justified and practitioners should be discouraged from per-
forming CAS without the use of such devices”.7
The recent Endarterectomy Versus Angioplasty in Pa-
tients With Symptomatic Severe Carotid Stenosis (EVA-3S)
trial issued a clinical alert in 2004 indicating that CAS should
be performed only with filter protection.8 The significance of
this finding is debatable, because the unprotected patients
were an average of 8 years older andmost of those strokes did
not occur during the procedure but later in the clinical course,
a fact that makes the lack of CP difficult to blame. The small
number of patients (15 in the no CP group) prevented the
difference from even being significant.
Some have even suggested that the use of CP signifi-
cantly reduces new MRI lesions after CAS, although this
was performed in the setting of a nonrandomized series.8
Despite the lack of scientific consensus on whether or not
distal filters are of benefit, the Centers for Medicare and
Medicaid Services recently issued a decision requiring suc-
cessful filter deployment to receive reimbursement for CAS.9
Our study raises some questions about this policy of manda-
tory CP device use and suggests that routine filter use, espe-
cially in octogenarians, may be associated with more new
y with severe stenosis of the internal carotid artery.
tuosity that made (C) subsequent filter advancement
nd E, Diffusion-weighted magnetic resonance imaging
ows).atom
f tor
. D aemboli after CAS rather than less emboli. Certainly, the ex-
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detected by DWMRI did not materialize.
As noted previously, cerebral filter use has not been
without its detractors. It has been shown that cerebral filter
use can be associated with ICA spasm, increased embolic
events, increased crossing profile for the initial wire access,
and technical misadventures in attempts to retrieve the
filter after stent deployment.10 The current generation of
antiembolic filters also have important limitations. First,
commercially available filters have pore sizes of 100 to 150
m. Meanwhile, high-volume microemboli 60 m have
been demonstrated in experimental models at all stages of
the procedure, including the initial wire passage.11
Other means of protecting against stroke have been
championed, including balloon occlusion and reversal of
flow, with some data suggesting superiority compared with
filter use.12,13 Proximal occlusion balloons with reversal of
flow offer the potential advantage of protection before the
lesion is crossed, avoidance of distal ICA spasm caused by
the filter, and protection from smaller fragments than is
possible with the current filters. Our results clearly cannot
be extended to these methods of CP.
It has been shown that although the number of patients
with ipsilateral lesions are similar with reversal of flow, the
total number of lesions is markedly reduced, as are the
number of emboli seen by transcranial Doppler imaging,
with the greatest benefit seen in octogenarians.14-16 No
randomized data comparing the technologies currently
exist; therefore, some combination of these technologies
will likely be necessary until better evidence exists.
In addition to the inherent limitations in filter technol-
ogy, one must also consider that filters cannot prevent
embolic events from the arch. As was seen in 19% of
patients in our study, a significant number of patients will
have evidence of contralateral emboli, many of which likely
arise from the aortic arch. Pinero et al17 examined this issue
by performing DW MRI imaging after all CAS procedures
and found that 32% of new MRI lesions occurred in terri-
tories other than the stented territory.17 They and others
have also used transcranial Doppler to demonstrate a sig-
nificant number of “hits” occurring during placement of
the angiographic sheath and filter deployment, before ad-
vancement of the stent.12 The exact timing of the micro-
emboli detected by the DW MRI in our study could have
been during the procedure or possibly in the early postpro-
cedural phase, as has been recently documented by Rapp
et al.18 This does not change the findings but raises a
question about the mechanism by which patients treated
with filter protection develop these lesions at an apparent
higher rate than those with no protection.
Our study has several obvious limitations because the
number of patients enrolled fell far short of the desired sample
size. Recruiting for the study proved to be very difficult.
Referring physicians were reluctant to allow their patients to
join the study because they were positive CP was necessary
with CAS. Patients eligible for the study also expressed hesi-
tation to be randomized owing to a fear of being randomized
to the noCP group.We found it evenmore difficult to recruitonce postmarketing studies became available after FDA ap-
proval of several stents and CP devices, providing an alterna-
tive that always included a CP device.
Another major weakness of our study is the uneven
distribution of octogenarians, potentially biasing the results
against the CP group. Despite randomization, the small
numbers involved failed to distribute the age groups evenly.
Age 80 has been repeatedly documented to increase
clinical adverse events, and three of four strokes in this
series were in octogenarians, with the last one in a 75-year-
old patient. The Stent-Protected Percutaneous Angioplasty
Versus Carotid Endarterectomy (SPACE) trial previously
demonstrated a 1.5-times increase in stroke and death in
patients aged 75 years compared with CEA.19 Stanziale
et al20 demonstrated an 8.0% vs 2.7% risk of 30-day stroke
rate in octogenarians compared with younger patients. The
CREST lead-in phase results demonstrated an increased
risk for every decade of age, with those patients aged 80
having a 12.1% risk of stroke and death compared with 1.7%
for patients aged60, 1.3% for patients 60 to 69, and 5.3%
for patients aged 70 to 79.21 All of these data suggest that
octogenarians are certainly at higher risk for ischemic
events affecting the interpretation of our data.
The use of MRI imaging as a surrogate for clinical
outcomes also has certain limitations, including that many
of these MRI findings are clinically silent.5 Diffusion-
weightedMRI is reported to be a sensitive means of detect-
ing acute ischemic lesions as early as 39 minutes after stroke
onset22 and is more sensitive than computed tomography
in detecting acute ischemia.23 In addition, DWMRI lesion
volume has been shown to correlate well with clinical
outcome, with accuracy of detecting pathologically identi-
fied infarcts in as many as 95% of lesions.24,25 Given these
facts, DW MRI seems to provide a suitable means of
assessing CP technology because actual event rates are
relatively low and would require exceedingly large numbers
of patients to reach statistical significance.
Whether our results can be generalized to all filters
available may be debated because they differ slightly in pore
size as well as their concentric or eccentric nature and their
deployment mechanism. Although our study tested only
one filter, we believe it is quite representative of the cate-
gory, and clinical results so far have been found to be
independent of the filter type.26
Our results are not unique. A Dutch, nonrandomized
study has previously shown that filter usewas associatedwith a
greater incidence of microemboli as measured by transcranial
Doppler.27 MacDonald28 found similar results to ours in a
randomized study also using DWMRI as well as transcranial
Doppler and chemical markers in venous effluents. That study
is available as a doctorate thesis and is yet unpublished other-
wise. To our knowledge, the data in this manuscript are
otherwise unique in providing a comparative assessment of
CAS with CP vs unprotected CAS in a randomized fashion.
Although we set out to show a reduction in ischemic
embolic event rates with CP, our data suggests a lack of
demonstrable benefit with a trend toward an increase in
newMRI lesions after CAS with the use of filters. Our data
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just as sizable as those with embolic events in the absence of
CP. The lack of major strokes in the CP group may argue
that at least large emboli are captured, but our numbers are
too small to offer such a reassuring statement.
CONCLUSION
Our data suggest that distal protection filters may not
be as effective as expected in reducing microemboli com-
pared with stenting without any filter protection. Their
routine use is associated with a significant number of DW
MRI defects, especially in a group of octogenarians. Our
results call into question the policy of mandatory filter use
in all patients. Larger studies are clearly warranted, as are
further investigations into alternative CP technologies.
AUTHOR CONTRIBUTIONS
Conception and design: ED, MH, TJ, EK, MM
Analysis and interpretation: JB, ED, MM
Data collection: JB, ED, EK, SD, MM
Writing the article: JB, MM
Critical revision of the article: JB, ED, MH, TJ, EK, SD,
MM
Final approval of the article: JB, ED,MH, TJ, EK, SD,MM
Statistical analysis: JB, ED, SD, MM
Obtained funding: Not applicable
Overall responsibility: MM
REFERENCES
1. Goodney PP, Schermerhorn ML, Powell RJ. Current status of carotid
artery stenting. J Vasc Surg 2006;43:406-11.
2. Wholey MH, Al Mubarek N, Wholey MH. Updated review of the
global carotid artery stent registry. Catheter Cardiovasc Interv 2003;60:
259-66.
3. Gray WA, Hopkins LN, Yadav S, Davis T, Wholey M, Atkinson R, et al.
Protected carotid stenting in high-surgical-risk patients: the ARCHeR
results. J Vasc Surg 2006;44:258-68.
4. Stanziale SF, Wholey MH, Boules TN, Selzer F, Makaroun MS. Deter-
mining in-stent stenosis of carotid arteries by duplex ultrasound criteria.
J Endovasc Ther 2005;12:346-53.
5. Jaeger HJ, Mathias KD, Hauth E, Drescher R, Gissler HM, Hennigs S,
et al. Cerebral ischemia detected with diffusion-weighted MR imaging
after stent implantation in the carotid artery. AJNR Am J Neuroradiol
2002;23:200-7.
6. Sztriha LK, Vörös E, Sas K, Szentgyörgyi R, Pócsik A, Barzó P, et al.
Favorable early outcome of carotid artery stenting without protection
devices. Stroke 2004;35:2862-6.
7. Ouriel K, Yadav J, Green RM. Standards of practice: carotid angioplasty
and stenting. J Vasc Surg 2004;39:916-7.
8. Macdonald S, McKevitt F, Venables GS, Cleveland TJ, Gaines PA.
Neurological outcomes after carotid stenting protected with the
NeuroShield filter compared to unprotected stenting. J Endovasc Ther
2002;9:777-85.
9. Centers for Medicare and Medicaid Services. Decision memo for per-
cutaneous transluminal angioplasty (PTA) of the carotid artery concur-
rent with stenting (CAG-00085R3). Available at: http://www.cms.
hhs.gov/mcd/viewdecisionmemo.asp?id194. Accessed Nov 14,
2007.
10. Kwon BJ, Han MH, Kang HS, Jung C. Protection filter-related events
in extracranial carotid artery stenting: a single-center experience.
J Endovasc Ther 2006;13:711-22.
11. Coggia M, Goëau-Brissonnière O, Duval JL, Leschi JP, Letort M,
Nagel MD. Embolic risk of the different stages of carotid bifurcationballoon angioplasty: an experimental study. J Vasc Surg 2000;31:
550-7.
12. Schmidt A, Diederich KW, Scheinert S, Bräunlich S, Olenburger T,
Biamino G, et al. Effect of two different neuroprotection systems on
microembolization during carotid artery stenting. J Am Coll Cardiol
2004;44:1966-9.
13. Rubartelli P, Brusa G, Arrigo A, Abbadessa F, Giachero C, Vischi M,
et al. Transcranial Doppler monitoring during stenting of the carotid
bifurcation: evaluation of two different distal protection devices in
preventing embolization. J Endovasc Ther 2006;13:436-42.
14. Grunwald IQ, Papanagiotou P, Struffert T, Politi M, Krick C, Romaike
BF, et al. Reversal of flow during carotid artery stenting: use of the
Parodi antiembolism system. Neuroradiology 2007;49:237-41.
15. Ribo M, Molina CA, Alvarez B, Rubiera M, Alvarez-Sabin J, Matas M.
Transcranial Doppler monitoring of transcervical carotid stenting with
flow reversal protection: a novel carotid revascularization technique.
Stroke 2006;37:2846-9.
16. Asakura F, Kawaguchi K, Sakaida H, Toma N, Matsushima S, Kuraishi
K, et al. Diffusion-weighted MR imaging in carotid angioplasty and
stenting with protection by the reversed carotid arterial flow. AJNR
Am J Neuroradiol 2006;27:753-8.
17. Piñero P, González A, Mayol A, Martínez E, González-Marcos JR,
Boza F, et al. Silent ischemia after neuroprotected percutaneous carotid
stenting: a diffusion-weighted MRI study. AJNR Am J Neuroradiol
2006;27:1338-45.
18. Rapp JH, Wakil L, Sawhney R, Pan XM, Yenari MA, Glastonbury C,
et al. Subclinical embolization after carotid artery stenting: new lesions
on diffusion-weighted magnetic resonance imaging occur postproce-
dure. J Vasc Surg 2007;45:867-72.
19. SPACE Collaborative Group, Ringleb PA, Allenberg J, Brückmann H,
Eckstein HH, Fraedrich G, et al. 30 day results from the SPACE trial of
stent-protected angioplasty versus carotid endarterectomy in symptom-
atic patients: a randomised non-inferiority trial. Lancet 2006;368:
1239-47.
20. Stanziale SF, Marone LK, Boules TN, Brimmeier JA, Hill K, Makaroun
MS, et al. Carotid artery stenting in octogenarians is associated with
increased adverse outcomes. J Vasc Surg 2006;43:297-304.
21. Hobson RW 2nd, Howard VJ, Roubin GS, Brott TG, Ferguson RD,
Popma JJ, et al. Carotid artery stenting is associated with increased
complications in octogenarians: 30-day stroke and death rates in the
CREST lead-in phase. J Vasc Surg 2004;40:1106-11.
22. Yoneda Y, Tokui K, Hanihara T, Kitagaki H, Tabuchi M, Mori E.
Diffusion-weighted magnetic resonance imaging: detection of ischemic
injury 39 minutes after onset in a stroke patient. Ann Neurol 1999;45:
794-797.
23. MullinsME, Schaefer PW, Sorensen AG,Halpern EF, AyH,He J, et al.
CT and conventional and diffusion-weighted MR imaging in acute
stroke: study in 691 patients at presentation to the emergency depart-
ment. Radiology 2002;224:353-60.
24. Kelly PJ, Hedley-Whyte ET, Primavera J, He J, Gonzalez RG.Diffusion
MRI in ischemic stroke compared to pathologically verified infarction.
Neurology 2001;56:914-20.
25. Lovblad KO, Baird AE, Schlaug G, Benfield A, Siewert B, Voetsch B,
et al. Ischemic lesion volumes in acute stroke by diffusion-weighted
magnetic resonance imaging correlate with clinical outcome. Ann Neu-
rol 1997;42:164-70.
26. Iyer V, de Donato G, Deloose K, Peeters P, Castriota F, Cremonesi A,
et al. The type of embolic protection does not influence the outcome in
carotid artery stenting. J Vasc Surg 2007;46:251-6.
27. Vos JA, van den Berg JC, Ernst SM, SuttorpMJ,OvertoomTT,Mauser
HW, et al. Carotid angioplasty and stent placement: comparison of
transcranial Doppler US data and clinical outcome with and without
filtering cerebral protection devices in 509 patients. Radiology 2005;
234:493-99.
28. MacDonald S. Neuroprotection and flow dynamics in carotid stenting
[doctoral thesis]. Sheffield, UK:University of Sheffield Main Library;
2004. Vol I & II [MO115661SH].Submitted Aug 17, 2007; accepted Nov 24, 2007.
